伊曲康唑治疗儿童孢子丝菌病113例临床疗效观察

发布时间：2018-09-07 11:28

【摘要】：目的：本研究通过对我院皮肤科2008年9月至2010年9月期间确诊的113例儿童孢子丝菌病患者采用伊曲康唑进行治疗观察,评估伊曲康唑治疗儿童孢子丝菌病的临床疗效及安全性,为有效治疗儿童孢子丝菌病、降低其复发率提供科学依据。方法：113例患儿口服伊曲康唑胶囊5mg/kg体重,每日1次,嘱患儿将药物与油性食物同服；疗程12周。若皮损炎症明显,加服抗生素1周。疗程期间以及疗程结束后2周末,每2周随访1次,观察并详细记录皮损变化,全身及局部药物不良反应,包括主、客观症状。治疗前后查血、尿常规及肝、肾功能。并于停药后1个月、3个月、6个月各随访一次,随访内容包括肝、肾功能变化及有无复发等。结果：伊曲康唑治疗儿童孢子丝菌病疗效显著,疗程2周时,总有效率为5.31%；疗程4周时,总有效率为40.71%；疗程6周时,总有效率为92.04%；疗程8周时,总有效率达98.23%。随着疗程的逐渐延长(2周至8周),总有效率不断升高,差异皆有显著性(P0.05)。而疗程至8周以后,总有效率不变,基愈病例数持续增多。停药后1个月随访113例患者中复发者2例,继续治疗1个月痊愈,肝功能异常者3例,继续随诊恢复正常,无肾功能改变；停药3个月随访复发1例,继续治疗1个月痊愈,肝肾功能变化的例数为0；停药后6个月随访无复发。结论：伊曲康唑治疗儿童孢子丝菌病疗效确切,不良反应较少,肝肾功能损害发生率较低,服用方便,为治疗的一种较好选择。
[Abstract]:Objective: to evaluate the efficacy and safety of itraconazole in the treatment of spore mycosis in children by using itraconazole in 113 children who were diagnosed in our department of dermatology from September 2008 to September 2010. To provide a scientific basis for the effective treatment of spore mycosis in children and the reduction of its recurrence rate. Methods 113 children were given itraconazole capsule (5mg/kg) once a day for 12 weeks. If inflammation is evident, take antibiotics for 1 week. The patients were followed up every 2 weeks during the course of treatment and 2 weeks after the treatment. The changes of skin lesions, systemic and local adverse drug reactions, including subjective and objective symptoms, were observed and recorded in detail. Blood, urine routine and liver and kidney function were examined before and after treatment. The patients were followed up for 1 month, 3 months and 6 months, including liver, renal function and recurrence. Results: itraconazole was effective in the treatment of spore mycosis in children. The total effective rate was 5.31 at 2 weeks, 40.71at 4 weeks, 92.044 at 6 weeks and 98.23 at 8 weeks. With the gradual extension of the course of treatment (2 weeks to 8 weeks), the total effective rate continuously increased, the differences were significant (P0.05). After 8 weeks of treatment, the total effective rate remained unchanged, and the number of cases of basal healing continued to increase. Two of 113 patients were followed up for 1 month after drug withdrawal, 2 patients were cured after 1 month of continuous treatment, 3 patients with abnormal liver function returned to normal and no changes of renal function were followed up, 1 case was followed up for 3 months, and 1 case was cured after 1 month of treatment. The number of patients with liver and kidney function changes was 0, and no recurrence occurred 6 months after withdrawal. Conclusion: itraconazole is a better choice for the treatment of spore mycosis in children, with less adverse reactions, lower incidence of liver and kidney function damage and convenient administration of itraconazole.
【学位授予单位】：吉林大学
【学位级别】：硕士
【学位授予年份】：2011
【分类号】：R756.6

【参考文献】